These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28504719)

  • 1. Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells.
    Kawauchi D; Ogg RJ; Liu L; Shih DJH; Finkelstein D; Murphy BL; Rehg JE; Korshunov A; Calabrese C; Zindy F; Phoenix T; Kawaguchi Y; Gronych J; Gilbertson RJ; Lichter P; Gajjar A; Kool M; Northcott PA; Pfister SM; Roussel MF
    Oncogene; 2017 Sep; 36(37):5231-5242. PubMed ID: 28504719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
    Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW
    J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
    Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BarTeL, a Genetically Versatile, Bioluminescent and Granule Neuron Precursor-Targeted Mouse Model for Medulloblastoma.
    Shackleford GM; Shi XH; Swanson KS; Mahdi MY; Gonzalez-Gomez I; Asgharzadeh S; D'Apuzzo M; Erdreich-Epstein A; Moats RA
    PLoS One; 2016; 11(6):e0156907. PubMed ID: 27310018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours.
    Seiboldt T; Zeiser C; Nguyen D; Celikyürekli S; Herter S; Najafi S; Stroh-Dege A; Meulenbroeks C; Mack N; Salem-Altintas R; Westermann F; Schlesner M; Milde T; Kool M; Holland-Letz T; Vogler M; Peterziel H; Witt O; Oehme I
    Br J Cancer; 2024 Sep; 131(4):763-777. PubMed ID: 38942989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.
    von Hoff K; Hartmann W; von Bueren AO; Gerber NU; Grotzer MA; Pietsch T; Rutkowski S
    Pediatr Blood Cancer; 2010 Mar; 54(3):369-76. PubMed ID: 19908297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression.
    Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B; Marshall GM
    Oncogene; 2009 Apr; 28(13):1605-15. PubMed ID: 19234491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bax deficiency prolongs cerebellar neurogenesis, accelerates medulloblastoma formation and paradoxically increases both malignancy and differentiation.
    Garcia I; Crowther AJ; Gama V; Miller CR; Deshmukh M; Gershon TR
    Oncogene; 2013 May; 32(18):2304-14. PubMed ID: 22710714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bmi1 overexpression in the cerebellar granule cell lineage of mice affects cell proliferation and survival without initiating medulloblastoma formation.
    Behesti H; Bhagat H; Dubuc AM; Taylor MD; Marino S
    Dis Model Mech; 2013 Jan; 6(1):49-63. PubMed ID: 23065639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An animal model of MYC-driven medulloblastoma.
    Pei Y; Moore CE; Wang J; Tewari AK; Eroshkin A; Cho YJ; Witt H; Korshunov A; Read TA; Sun JL; Schmitt EM; Miller CR; Buckley AF; McLendon RE; Westbrook TF; Northcott PA; Taylor MD; Pfister SM; Febbo PG; Wechsler-Reya RJ
    Cancer Cell; 2012 Feb; 21(2):155-67. PubMed ID: 22340590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.
    Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH
    Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth.
    Hatton BA; Knoepfler PS; Kenney AM; Rowitch DH; de Alborán IM; Olson JM; Eisenman RN
    Cancer Res; 2006 Sep; 66(17):8655-61. PubMed ID: 16951180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.
    Northcott PA; Fernandez-L A; Hagan JP; Ellison DW; Grajkowska W; Gillespie Y; Grundy R; Van Meter T; Rutka JT; Croce CM; Kenney AM; Taylor MD
    Cancer Res; 2009 Apr; 69(8):3249-55. PubMed ID: 19351822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors.
    Kenney AM; Cole MD; Rowitch DH
    Development; 2003 Jan; 130(1):15-28. PubMed ID: 12441288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
    Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
    BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mouse model of the most aggressive subgroup of human medulloblastoma.
    Kawauchi D; Robinson G; Uziel T; Gibson P; Rehg J; Gao C; Finkelstein D; Qu C; Pounds S; Ellison DW; Gilbertson RJ; Roussel MF
    Cancer Cell; 2012 Feb; 21(2):168-80. PubMed ID: 22340591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling medulloblastoma in vivo and with human cerebellar organoids.
    Ballabio C; Anderle M; Gianesello M; Lago C; Miele E; Cardano M; Aiello G; Piazza S; Caron D; Gianno F; Ciolfi A; Pedace L; Mastronuzzi A; Tartaglia M; Locatelli F; Ferretti E; Giangaspero F; Tiberi L
    Nat Commun; 2020 Jan; 11(1):583. PubMed ID: 31996670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation.
    Takei H; Nguyen Y; Mehta V; Chintagumpala M; Dauser RC; Adesina AM
    J Neurosurg Pediatr; 2009 Jan; 3(1):61-5. PubMed ID: 19119907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models.
    Rodriguez-Blanco J; Salvador AD; Suter RK; Swiderska-Syn M; Palomo-Caturla I; Kliebe V; Shahani P; Peterson K; Turos-Cabal M; Vieira ME; Wynn DT; Howell AJ; Yang F; Ban Y; McCrea HJ; Zindy F; Danis E; Vibhakar R; Jermakowicz A; Martin V; Coss CC; Harris BT; de Cubas A; Chen XS; Barnoud T; Roussel MF; Ayad NG; Robbins DJ
    J Clin Invest; 2024 Jun; 134(15):. PubMed ID: 38885332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
    Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
    Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.